Board of Directors

The Board of Directors: protecting the company’s interests 


The Executive Committee submits strategic decisions to the Board of Directors for approval. The Board’s main job is to safeguard the Group’s interests, ensuring its continued success with an eye to creating value.

Dr André Choulika, Chairman of the Board of Directors and CEO
André Choulika, Ph.D., is one of the founders of Cellectis and has been Chairman of the Board and Chief Executive Officer since 2000. He has also been President of Calyxt since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. André Choulika also has management training from the HEC (Challenge +).

Laurent Arthaud, Independent Director
Laurent Arthaud has served as a member of Cellectis’ Board of Directors since 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement (formerly CDC Enterprises, a subsidiary of Caisse des Dépôts) since 2012. From 2006 to 2012, Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Mr. Arthaud is a graduate of the École Polytechnique and the l’École Nationale de Statistique et d’Administration Économique.

Pierre Bastid, Independent Director
Pierre Bastid has served as a member of Cellectis’ Board of Directors since 2011. He has been a member of the Board of Directors of HOUGOU S.A. since 2011. He also currently serves on the Boards of Directors of HOUGOU Développement S.A., Louise 342-344 S.A., Crystal Sunrise S.A., Shango S.A., Hebioso S.A., Les Bastidons S.A., Nepteam S.A.S., Krishna S.C. and La Chartreuse B S.C.

Alain Godard, Independent Director
Mr. Godard is a graduate of the École Nationale Supérieure Agronomique de Toulouse. He began his agronomy career in 1967 in Africa as a researcher at the l’Institut de Recherche pour les Huiles et Oléagineux (institute for research on oils and oleaginous plants). He has served as a member of Cellectis’ Board of Directors since October 2007. He has been the Chief Executive Officer of SARL Godard & Co. since June 2009, and he also serves on the Board of Directors of Fermentalg SA.

Jean-Marie Messier, Independent Director
Jean-Marie Messier has served as a member of our Board of Directors since May 2015. He is co-founder and head of Messier Maris & Associés, an international investment banking firm. Mr. Messier has served on the Board of Directors of Rentabiliweb Group since May 2011. After graduating from the French university, Ecole Polytechnique, Mr. Messier attended the Ecole Nationale d’Administration. He became Managing Partner at Lazard Frères in 1988, a position he held for six years. Prior to this, he was responsible for the French Government’s Privatization plan. Mr. Messier served as President of Vivendi Universal from 1994 to 2002. During these years, he founded the mobile firm Cegetel and turned Vivendi into a conglomerate focused on two core activities: utilities and communications, selling off assets in other areas.

Dr Annick Schwebig, MD, Independent Director
Annick Schwebig, MD, has served as a member of Cellectis’ Board of Directors since 2011. In 2000, she founded the French subsidiary of Actelion, of which she is the General Manager. Actelion is a biopharmaceuticals company specializing in innovative treatments to serve unmet medical needs. A graduate of the University of Paris medical school, Dr. Schwebig worked as a senior manager at the biopharmaceuticals company Bristol-Myers Squibb for 17 years from 1983 to 2000.

Dr Mathieu Simon, MD, Director, Executive Vice-President, Chief Operating Officer
Mathieu Simon, MD, has served as Executive Vice-President Chief Executive Officer of Cellectis Therapeutics since 2012 and as Chief Operating Officer since 2013. Dr Mathieu Simon is also Member of Cellectis Board of Directors since 2013. Prior to joining Cellectis, Dr. Simon was Senior Vice President Head of Global Pharmaceutical Operations at Pierre Fabre S.A. From 1994 to 2010, Dr Simon has served at Wyeth Pharmaceuticals in both senior corporate and regional roles (Head of International Marketing and Medical Affairs and managing Director of several Wyeth Affiliates). Dr Simon today is an advisor at the European Commission D.G. Research and Innovation with a special expertise in Market Access and pricing initiation. In addition to his Cellectis role, Dr Simon is also Senior Strategic Advisor at Messier Maris Partners, an international investment-banking boutique located in New York and Paris.

Dr David Sourdive, PhD, Director, Executive Vice President Corporate Development
David Sourdive, Ph.D., is a co-founder of Cellectis and has held the position of Executive Vice President, Corporate Development from 2008 to 2016. His current position is Executive Vice President, Technical Operations. Dr. Sourdive has also been a member of Cellectis’ Board of Directors since 2000. Since 2014, Dr. Sourdive has also served on the board of directors of Mediterranean Institute for Life Sciences. David Sourdive graduated from the École Polytechnique and received his Ph.D. in molecular virology at the Institut Pasteur. He also has management training from the HEC (Challenge +).

Independent Directors according to Nasdaq rules